Richard Giosa
Pulmonary Disease · Meriden, CTNPI 1659363042
Payments from drug & device makers
Across 174 payments — averaging $18.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$915
- AstraZeneca$431
- Boehringer Ingelheim$315
- Grifols USA, LLC$165
- Advanced Respiratory, Inc$160
- Mallinckrodt Hospital Products Inc.$151
- plus $1K from 20 others
What the payments were for
- Food & beverage$3,17998%
- Education$772%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 73 | $915 |
| AstraZeneca(2 entities) | 23 | $431 |
| Boehringer Ingelheim | 12 | $315 |
| Grifols USA, LLC | 7 | $165 |
| Advanced Respiratory, Inc | 3 | $160 |
| Mallinckrodt Hospital Products Inc. | 4 | $151 |
| Genentech USA, Inc. | 7 | $143 |
| Pfizer | 5 | $123 |
| Amgen | 5 | $98 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $97 |
| Mylan Specialty L.p. | 4 | $85 |
| Novartis | 3 | $69 |
| Regeneron Healthcare Solutions, Inc. | 3 | $66 |
| Philips North America LLC | 4 | $63 |
| ANI Pharmaceuticals, Inc. | 2 | $58 |
| Boston Scientific | 1 | $51 |
| AbbVie | 2 | $41 |
| Electromed, Inc. | 3 | $40 |
| Nabriva Therapeutics, PLC | 2 | $34 |
| Phadia US Inc. | 1 | $29 |
| CSL Behring | 1 | $28 |
| Covis Pharma GmbH | 1 | $26 |
| Sanofi | 1 | $19 |
| United Therapeutics Corporation | 1 | $19 |
| Insmed, Inc. | 1 | $18 |
| Optinose US, Inc. | 1 | $14 |
How this compares
$3,256 in reported general payments places this provider in the 60th percentile of 255 pulmonary disease providers in Connecticut.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 198 | $190,555 |
| GlassiaAlpha-1-Proteinase Inhibitor | 12 | $131,098 |
| ZemairaAlpha-1-Proteinase Inhibitor | 12 | $106,127 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 75 | $58,222 |
| Breo ElliptaFluticasone/Vilanterol | 80 | $47,539 |
| NucalaMepolizumab | 12 | $45,148 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 19 | $20,488 |
| Spiriva HandihalerTiotropium Bromide | 26 | $20,294 |
| Spiriva RespimatTiotropium Bromide | 15 | $19,477 |
| Advair HfaFluticasone Propion/Salmeterol | 31 | $10,506 |
| SymbicortBudesonide/Formoterol Fumarate | 26 | $8,121 |
| Advair DiskusFluticasone Propion/Salmeterol | 19 | $7,230 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 26 | $6,543 |
| DuleraMometasone/Formoterol | 13 | $6,465 |
| Fluticasone-VilanterolFluticasone/Vilanterol | 15 | $6,409 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Nucala | $915 | $341,463365 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Glassia | $97 | $131,09812 claims |
| CSL BehringZemaira | $28 | $106,12712 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $315 | $39,96534 claims |
| AstraZenecaSymbicort | $431 | $8,12126 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 255 pulmonary disease providers in Connecticut.
Other pulmonary disease in Meriden
- Geoffrey ChuppNew Haven$3.1M
- Jonathan KoffNew Haven$1.1M
- Naftali KaminskiNew Haven$1M
- Danielle Antin-OzerkisNew Haven$1M
- Mircea BadaraNew Britain$1M
- Mridu GulatiNew Haven$536K
- Phillip JosephNew Haven$488K
- Tapas BandyopadhyayWest Hartford$483K
- Raj ParikhHartford$419K
- Patrick TroyHartford$385K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.